TruScreen Group Limited (NZX/ASX:TRU), a company that develops and sells cervical cancer screening devices, announced today that its CEO, Dr. Beata Edling, has resigned for personal reasons.

Edling, who led the company since October 2022, will help with the transition to an interim CEO in the coming weeks. She will also continue to support TruScreen’s business in Poland and central Europe as a consultant.

Edling’s tenure as CEO saw TruScreen achieve significant growth and recognition in the global market. The company’s technology was endorsed by the national health authorities of China, Vietnam, and Mexico, setting the foundation for further expansion.

The board and the staff of TruScreen thanked Edling for her contribution and wished her well. Mr Martin Dillon, a former CEO of TruScreen from 2013 to 2019, will take over as interim CEO. Dillon has extensive experience in the industry and was responsible for launching the TruScreen Ultra2 device and listing the company on the NZX.

Chairman Tony Ho said that the company respects Edling’s decision and expects minimal disruption to its ongoing business. He also said that the company’s live Rights Offer to shareholders will not be affected by this event.